全文获取类型
收费全文 | 1795789篇 |
免费 | 136503篇 |
国内免费 | 11435篇 |
专业分类
耳鼻咽喉 | 22673篇 |
儿科学 | 56918篇 |
妇产科学 | 48195篇 |
基础医学 | 252838篇 |
口腔科学 | 50621篇 |
临床医学 | 165057篇 |
内科学 | 347950篇 |
皮肤病学 | 39857篇 |
神经病学 | 136366篇 |
特种医学 | 67753篇 |
外国民族医学 | 312篇 |
外科学 | 268138篇 |
综合类 | 57104篇 |
现状与发展 | 27篇 |
一般理论 | 536篇 |
预防医学 | 130306篇 |
眼科学 | 43375篇 |
药学 | 134986篇 |
118篇 | |
中国医学 | 10274篇 |
肿瘤学 | 110323篇 |
出版年
2021年 | 16044篇 |
2019年 | 17415篇 |
2018年 | 23886篇 |
2017年 | 18721篇 |
2016年 | 19873篇 |
2015年 | 23951篇 |
2014年 | 32412篇 |
2013年 | 43705篇 |
2012年 | 61172篇 |
2011年 | 64744篇 |
2010年 | 38475篇 |
2009年 | 35151篇 |
2008年 | 57651篇 |
2007年 | 60900篇 |
2006年 | 61336篇 |
2005年 | 58671篇 |
2004年 | 54824篇 |
2003年 | 51987篇 |
2002年 | 49566篇 |
2001年 | 94176篇 |
2000年 | 96065篇 |
1999年 | 79496篇 |
1998年 | 20793篇 |
1997年 | 18258篇 |
1996年 | 17871篇 |
1995年 | 18028篇 |
1994年 | 16431篇 |
1993年 | 14776篇 |
1992年 | 58273篇 |
1991年 | 56115篇 |
1990年 | 53703篇 |
1989年 | 51369篇 |
1988年 | 46663篇 |
1987年 | 45410篇 |
1986年 | 42574篇 |
1985年 | 40325篇 |
1984年 | 29491篇 |
1983年 | 24967篇 |
1982年 | 13920篇 |
1979年 | 25556篇 |
1978年 | 17571篇 |
1977年 | 14882篇 |
1976年 | 13864篇 |
1975年 | 14553篇 |
1974年 | 17658篇 |
1973年 | 16937篇 |
1972年 | 15680篇 |
1971年 | 14451篇 |
1970年 | 13429篇 |
1969年 | 12521篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Kara S. Tanaka MD Veronica R. Andaya BA Steven W. Thorpe MD Kenneth R. Gundle MD James B. Hayden MD Yee-Cheen Duong MD Raffi S. Avedian MD David G. Mohler MD Lee J. Morse MD Melissa N. Zimel MD Richard J. O'Donnell MD Andrew Fang MD Robert Lor Randall MD Tina H. Tran BS Christin New BA Rosanna L. Wustrack MD other members of Study Group FORCE 《Journal of surgical oncology》2023,127(1):148-158
2.
S. Liu A. E. Patanwala J. M. Naylor N. Levy R. Knaggs J. A. Stevens B. Bugeja D. Begley K. E. Khor E. Lau R. Allen S. Adie J. Penm 《Anaesthesia》2023,78(10):1237-1248
Modified-release opioids are often prescribed for the management of moderate to severe acute pain following total hip and knee arthroplasty, despite recommendations against their use due to increasing concerns regarding harm. The primary objective of this multicentre study was to examine the impact of modified-release opioid use on the incidence of opioid-related adverse events compared with immediate-release opioid use, among adult inpatients following total hip or knee arthroplasty. Data for total hip and knee arthroplasty inpatients receiving an opioid analgesic for postoperative analgesia during hospitalisation were collected from electronic medical records of three tertiary metropolitan hospitals in Australia. The primary outcome was the incidence of opioid-related adverse events during hospital admission. Patients who received modified with or without immediate-release opioids were matched to those receiving immediate-release opioids only (1:1) using nearest neighbour propensity score matching with patient and clinical characteristics as covariates. This included total opioid dose received. In the matched cohorts, patients given modified-release opioids (n = 347) experienced a higher incidence of opioid-related adverse events overall, compared with those given immediate-release opioids only (20.5%, 71/347 vs. 12.7%, 44/347; difference in proportions 7.8% [95%CI 2.3–13.3%]). Modified-release opioid use was associated with an increased risk of harm when used for acute pain during hospitalisation after total hip or knee arthroplasty. 相似文献
3.
Maja Popovic Gorana Matovina-Brko Masa Jovic Lazar S Popovic 《World journal of clinical oncology》2022,13(1):28-38
Renal cell cancer (RCC) represents 2%-3% of all adulthood cancers and is the most common malignant neoplasm of the kidney (90%). In the mid-nineties of the last century, the standard of treatment for patients with metastatic RCC was cytokines. Sunititib and pazopanib were registered in 2007 and 2009, respectively, and have since been the standard first-line treatment for metastatic clear cell RCC (mccRCC). Renal cell cancer is a highly immunogenic tumor with tumor infiltrating cells, including CD8+ T lymphocytes, dendritic cells, natural killer cells (NK) and macrophages. This observation led to the design of new clinical trials in which patients were treated with immunotherapy. With the growing evidence that proangiogenic factors can have immunomodulatory effects on the host’s immune system, the idea of combining angiogenic drugs with immunotherapy has emerged, and new clinical trials have been designed. In the last few years, several therapeutic options have been approved [immunotherapy and immunotherapy/tyrosine kinase inhibitors (TKI)] for the first-line treatment of mccRCC. Nivolumab/ipilimumab is approved for the treatment of patients with inter mediate and poor prognoses. Several checkpoint inhibitors (pembrolizumab, nivolumab, avelumab) in combination with TKI (axitinib, lenvatinib, cabozan tinib) are approved for the treatment of patients regardless of their International mRCC Database Consortium prognostic group and PD-L1 expression. There is no specific and ideal biomarker that could help in selecting the ideal patient for the appropriate first-line treatment. 相似文献
4.
Rozhkov V. P. Trifonov M. I. Soroko S. I. 《Neuroscience and behavioral physiology》2022,52(3):383-394
Neuroscience and Behavioral Physiology - We present here results from analysis of the formation of brain bioelectrical activity in children and adolescents living in the northern region of Russia... 相似文献
5.
Wan-Jun Zhang Li-Qiang Wu Jun Wang Sheng-Yun Lin Bo Wang 《World Journal of Clinical Cases》2022,10(23):8242-8248
ABSTRACT
BACKGROUND
Hepatitis-associated aplastic anemia (HAAA) is a rare condition. Patients with HAAA usually present with acute hepatitis, jaundice and significantly increased transaminase. After 1–2 mo, hepatitis gradually improves, but progressive hemocytopenia, bone marrow hematopoietic failure, and severe or extremely severe aplastic anemia are manifest. Most cases of HAAA are fulminant and usually lethal if left untreated. The literature on Epstein–Barr virus (EBV)-associated HAAA is sparse.
CASE SUMMARY
We report a 30-year-old man who was admitted to our hospital because of pale yellow urine and skin with a simultaneous decrease in peripheral blood ternary cells. We made a diagnosis of EBV-associated HAAA. The treatment strategy for this patient included eltrombopag, an immunosuppressive regimen of rabbit anti-human thymocyte immunoglobulin, cyclosporine, and supportive care. The patient was discharged in normal physical condition after five months. A hemogram performed on follow-up revealed that he had achieved a complete response.
CONCLUSION
Eltrombopag plus anti-thymocyte globubin and cyclosporine may be a therapeutic option for EBV-associated HAAA.Larger studies are warranted to confirm. 相似文献
6.
7.
目的探讨麻痹性痴呆(GPI)患者脑血流量(CBF)特点及其与认知障碍的相关性。 方法纳入2018年1月至2019年12月于首都医科大学附属北京地坛医院就诊的GPI患者18例和健康体检者18例(健康对照组),采用蒙特利尔认知评估量表评定认知功能。采用磁共振动脉自旋标记技术扫描评估其各个脑区CBF,并进一步应用Spearman相关分析CBF异常区域与认知功能的相关性。 结果GPI患者蒙特利尔认知评估量表评分低于健康对照组[(16.00 ± 7.19)vs. (27.90 ± 1.21):t =-7.853、P < 0.001)]。18例GPI患者中,头颅MRI正常5例,脑白质病变1例,脑萎缩9例,3例患者同时存在脑萎缩和脑白质病变。健康对照组头颅MRI均未见异常。GPI患者脑13、14、28、37、38、41、42、43、44、46、48、49、50、51、52、69、70、77、78、83、84、88、109、117、165、166、167、168、169、177、178、179、187、188、211、212、213、214、215、216、219、223、227、237和238区CBF显著高于健康对照组(P均< 0.001)。GPI患者认知障碍中的注意力障碍与脑69、70、77、78、166和168区CBF异常有一定的负相关性(r =-0.476、P = 0.046,r =-0.487、P = 0.034,r =-0.604、P = 0.008,r = -0.545、P = 0.019,r =-0.544、P = 0.02,r =-0.522、P = 0.026)。 结论GPI患者存在全脑血流量升高。GPI患者认知功能障碍中的注意力障碍可能与局部脑区血流量升高有一定相关性。局部CBF越高,注意力障碍越严重。这可能也是GPI发病机制之一。 相似文献
8.
目的 了解江苏省省级专科护士工作投入现状及影响因素,为针对性管理提供参考。方法 采用一般资料调查问卷与专科护士工作投入量表对2 472名省级专科护士进行调查分析。结果 专科护士工作投入总均分为4.06±0.46;多元线性回归分析显示,性别、聘任方式、专科类别、工作类型、出任专科护理门诊、论文发表是专科护士工作投入的影响因素(P<0.05,P<0.01)。结论 专科护士工作投入水平较高,其影响因素较多,护理管理者应关注专科护士专业开展现况,采取针对性措施支持专科护理的有效开展,从而进一步提高专科护士的工作投入水平。 相似文献
9.
Forgiveness has been found one substantial element in the recovery for women survivors from intimate partner violence following the termination of the abusive relationship. To further investigate the details of forgiveness in this specific context, the present study explored the process of forgiveness using grounded theory. In-depth and semi-structured interviews were conducted with 25 Chinese women survivors of IPV. The findings suggest that forgiveness is a strength-based process including empowerment, transformation, and integration phases. In the empowerment phase, survivors obtain strength at the intrapersonal, behavioural, and interpersonal levels. In the transformation phase, survivors complete cognitive transformation for their IPV experiences and emotional transformation towards former partners. In the integration phase, survivors—now freed from the past—reflect upon and apply the changes they have undergone. Two trajectories in the process were found. One trajectory is going through stages sequentially and the other trajectory is experiencing back and forth between empowerment and transformation stages before moving into the integration stage. The study's findings broaden our knowledge of the strength-based forgiveness process that women survivors of IPV undergo during recovery. Practitioners and policymakers could develop programmes and policies that support forgiveness by holistically facilitating their recovery and empowerment like assistance in dealing with life difficulties and promoting their reconnection with social networks. To improve the transferability and validity of the findings, the forgiveness of survivors of IPV could be explored in a diverse sample (e.g., survivors with low educational background or live in the rural area). 相似文献
10.